|
1.
|
Sobin L, Gospodarowicz M and Wittekind C:
TNM Classification of Malignant Tumors. 7th edition. John Wiley
& Sons, Inc; Hoboken, NJ: 2009
|
|
2.
|
Naito Y, Saito K, Shiiba K, Ohuchi A,
Saigenji K, Nagura H and Ohtani H: CD8+T cells
infiltrated within cancer cell nests as a prognostic factor in
human colorectal cancer. Cancer Res. 58:3491–3494. 1998.PubMed/NCBI
|
|
3.
|
Guidoboni M, Gafà R, Viel A, Doglioni C,
Russo A, Santini A, Del Tin L, Macrì E, Lanza G, Boiocchi M and
Dolcetti R: Microsatellite instability and high content of
activated cytotoxic lymphocytes identify colon cancer patients with
a favorable prognosis. Am J Pathol. 159:297–304. 2001. View Article : Google Scholar
|
|
4.
|
Wakabayashi O, Yamazaki K, Oizumi S,
Hommura F, Kinoshita I, Ogura S, Dosaka-Akita H and Nishimura M:
CD4+T cells in cancer stroma, not CD8+T cells
in cancer cell nests, are associated with favorable prognosis in
human non-small cell lung cancers. Cancer Sci. 94:1003–1009.
2003.
|
|
5.
|
Prall F, Dührkop T, Weirich V, Ostwald C,
Lenz P, Nizze H and Barten M: Prognostic role of
CD8+tumor-infiltrating lymphocytes in stage III
colorectal cancer with and without microsatellite instability. Hum
Pathol. 35:808–816. 2004.
|
|
6.
|
Fukunaga A, Miyamoto M, Cho Y, Murakami S,
Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y,
Hiraoka K, Itoh T, Morikawa T, Okushiba S, Kondo S and Katoh H:
CD8+tumor-infiltrating lymphocytes together with
CD4+tumor-infiltrating lymphocytes and dendritic cells
improve the prognosis of patients with pancreatic adenocarcinoma.
Pancreas. 28:e26–e31. 2004.
|
|
7.
|
Zlobec I, Minoo P, Baumhoer D, Baker K,
Terracciano L, Jass JR and Lugli A: Multimarker phenotype predicts
adverse survival in patients with lymph node-negative colorectal
cancer. Cancer. 112:495–502. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Leffers N, Gooden MJ, de Jong RA,
Hoogeboom BN, ten Hoor KA, Hollema H, Boezen HM, van der Zee AG,
Daemen T and Nijman HW: Prognostic significance of
tumor-infiltrating T-lymphocytes in primary and metastatic lesions
of advanced stage ovarian cancer. Cancer Immunol Immunother.
58:449–459. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
de Jong RA, Leffers N, Boezen HM, ten Hoor
KA, van der Zee AG, Hollema H and Nijman HW: Presence of
tumor-infiltrating lymphocytes is an independent prognostic factor
in type I and II endometrial cancer. Gynecol Oncol. 114:105–110.
2009.PubMed/NCBI
|
|
10.
|
Shah W, Yan X, Jing L, Zhou Y, Chen H and
Wang Y: A reversed CD4/CD8 ratio of tumor-infiltrating lymphocytes
and a high percentage of CD4(+) FOXP3(+) regulatory T cells are
significantly associated with clinical outcome in squamous cell
carcinoma of the cervix. Cell Mol Immunol. 8:59–66. 2011.PubMed/NCBI
|
|
11.
|
Seethala RR, Hunt JL, Baloch ZW, Livolsi
VA and Leon Barnes E: Adenoid cystic carcinoma with high-grade
transformation: a report of 11 cases and a review of the
literature. Am J Surg Pathol. 31:1683–1694. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Leuverink EM, Brennan BA, Crook ML,
Doherty DA, Hammond IG, Ruba S and Stewart CJ: Prognostic value of
mitotic counts and Ki-67 immunoreactivity in adult-type granulosa
cell tumour of the ovary. J Clin Pathol. 61:914–919. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Wrba F, Reiner A, Markis-Ritzinger E,
Holzner JH, Reiner G and Spona J: Prognostic significance of
immunohistochemical parameters in breast carcinomas. Pathol Res
Pract. 183:277–283. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Bruner JM: Neuropathology of malignant
gliomas. Semin Oncol. 21:126–138. 1994.PubMed/NCBI
|
|
15.
|
Greenblatt MS, Grollman AP and Harris CC:
Deletions and insertions in the p53 tumor suppressor gene in human
cancers: confirmation of the DNA polymerase slippage/misalignment
model. Cancer Res. 56:2130–2136. 1996.PubMed/NCBI
|
|
16.
|
Bosari S, Viale G, Radaelli U, Bossi P,
Bonoldi E and Coggi G: p53 accumulation in ovarian carcinomas and
its prognostic implications. Hum Pathol. 24:1175–1179. 1993.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Fontanini G, Vignati S, Lucchi M, Mussi A,
Calcinai A, Boldrini L, Chiné S, Silvestri V, Angeletti CA, Basolo
F and Bevilacqua G: Neoangiogenesis and p53 protein in lung cancer:
their prognostic role and their relation with vascular endothelial
growth factor (VEGF) expression. Br J Cancer. 75:1295–1301. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Assimakopoulos D, Kolettas E, Zagorianakou
N, Evangelou A, Skevas A and Agnantis NJ: Prognostic significance
of p53 in the cancer of the larynx. Anticancer Res. 20:3555–3564.
2000.PubMed/NCBI
|
|
19.
|
Pancione M, Forte N, Fucci A, Sabatino L,
Febbraro A, Di Blasi A, Daniele B, Parente D and Colantuoni V:
Prognostic role of beta-catenin and p53 expression in the
metastatic progression of sporadic colorectal cancer. Hum Pathol.
41:867–876. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Sumithran E, Susil BJ and Looi LM: The
prognostic significance of grading in borderline mucinous tumors of
the ovary. Hum Pathol. 19:15–18. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Elston CW and Ellis IO: Pathological
prognostic factors in breast cancer. I. The value of histological
grade in breast cancer: experience from a large study with
long-term follow-up. CW Elston and IO Ellis. Histopathology.
1991.19:403–410, Histopathology 41: 151–153, 2002.
|
|
22.
|
Van Eeden S, Quaedvlieg PF, Taal BG,
Offerhaus GJ, Lamers CB and Van Velthuysen ML: Classification of
low-grade neuroendocrine tumors of midgut and unknown origin. Hum
Pathol. 33:1126–1132. 2002.PubMed/NCBI
|
|
23.
|
Kadota K, Suzuki K, Colovos C, Sima CS,
Rusch VW, Travis WD and Adusumilli PS: A nuclear grading system is
a strong predictor of survival in epitheloid diffuse malignant
pleural mesothelioma. Mod Pathol. 25:260–271. 2012.PubMed/NCBI
|
|
24.
|
Storr SJ, Safuan S, Mitra A, Elliott F,
Walker C, Vasko MJ, Ho B, Cook M, Mohammed RA, Patel PM, Ellis IO,
Newton-Bishop JA and Martin SG: Objective assessment of blood and
lymphatic vessel invasion and association with macrophage
infiltration in cutaneous melanoma. Mod Pathol. 25:493–504. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Pilgrim C, Usatoff V and Evans PM: A
review of the surgical strategies for the management of gallbladder
carcinoma based on T stage and growth type of the tumour. Eur J
Surg Oncol. 35:903–907. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Mekeel KL and Hemming AW: Surgical
management of gall-bladder carcinoma: a review. J Gastrointest
Surg. 11:1188–1193. 2007. View Article : Google Scholar
|
|
27.
|
Wakai T, Shirai Y, Yokoyama N, Nagakura S,
Watanabe H and Hatakeyama K: Early gallbladder carcinoma does not
warrant radical resection. Br J Surg. 88:675–678. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Nakakubo Y, Miyamoto M, Cho Y, Hida Y,
Oshikiri T, Suzuoki M, Hiraoka K, Itoh T, Kondo S and Katoh H:
Clinical significance of immune cell infiltration within
gallbladder cancer. Br J Cancer. 89:1736–1742. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Ajiki T, Onoyama H, Yamamoto M, Asaka K,
Fujimori T, Maeda S and Saitoh Y: p53 protein expression and
prognosis in gallbladder carcinoma and premalignant lesions.
Hepatogastroenterology. 43:521–526. 1996.PubMed/NCBI
|
|
30.
|
Hidalgo Grau LA, Badia JM, Salvador CA,
Monsó TS, Canaleta JF, Nogués JM and Sala JS: Gallbladder
carcinoma: the role of p53 protein overexpression and Ki-67 antigen
expression as prognostic markers. HPB; Oxford: 6. pp. 174–180.
2004
|
|
31.
|
Kim YW, Huh SH, Park YK, Yoon TY, Lee SM
and Hong SH: Expression of the c-erb-B2 and p53 protein in
gallbladder carcinomas. Oncol Rep. 8:1127–1132. 2001.PubMed/NCBI
|
|
32.
|
Jarnagin WR, Klimstra DS, Hezel M, Gonen
M, Fong Y, Roggin K, Cymes K, DeMatteo RP, D’Angelica M, Blumgart
LH and Singh B: Differential cell cycle-regulatory protein
expression in biliary tract adenocarcinoma: correlation with
anatomic site, pathologic variables, and clinical outcome. J Clin
Oncol. 24:1152–1160. 2006. View Article : Google Scholar
|
|
33.
|
Kim WB, Han HJ, Lee HJ, Park SS, Song TJ,
Kim HK, et al: Expression and clinical significance of cell cycle
regulatory proteins in gallbladder and extrahepatic bile duct
cancer. Ann Surg Oncol. 16:23–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Lee CS and Pirdas A: p53 protein
immunoreactivity in cancers of the gallbladder, extrahepatic bile
ducts and ampulla of Vater. Pathology. 27:117–120. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Chang HJ, Yoo BC, Kim SW, Lee BL and Kim
WH: Significance of PML and p53 protein as molecular prognostic
markers of gallbladder carcinomas. Pathol Oncol Res. 13:326–335.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Roa EI, Lantadilla HS, Ibacache SG and de
Aretxabala UX: p53 and p27 gene expression in subserosal
gallbladder carcinoma. Rev Med Chil. 137:1017–1022. 2009.(In
Spanish).
|
|
37.
|
Wistuba II, Gazdar AF, Roa I and
Albores-Saavedra J: p53 protein overexpression in gallbladder
carcinoma and its precursor lesions: an immunohistochemical study.
Hum Pathol. 27:360–365. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Kamel D, Pääkkö P, Nuorva K, Vähäkangas K
and Soini Y: p53 and c-erbB-2 protein expression in adenocarcinomas
and epithelial dysplasias of the gall bladder. J Pathol. 170:67–72.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
39.
|
Itoi T, Watanabe H, Yoshida M, Ajioka Y,
Nishikura K and Saito T: Correlation of p53 protein expression with
gene mutation in gall-bladder carcinomas. Pathol Int. 47:525–530.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Oohashi Y, Watanabe H, Ajioka Y and
Hatakeyama K: p53 immunostaining distinguishes malignant from
benign lesions of the gall-bladder. Pathol Int. 45:58–65. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
41.
|
Shrestha ML, Miyake H, Kikutsuji T and
Tashiro S: Prognostic significance of Ki-67 and p53 antigen
expression in carcinomas of bile duct and gallbladder. J Med
Invest. 45:95–102. 1998.PubMed/NCBI
|
|
42.
|
Kohya N and Miyazaki K: Hepatectomy of
segment 4a and 5 combined with extra-hepatic bile duct resection
for T2 and T3 gallbladder carcinoma. J Surg Oncol. 97:498–502.
2008. View Article : Google Scholar : PubMed/NCBI
|
